Relutrigine
Praxis Precision Medicines (PRAX)
Decision dateDec 27, 2026
42 days away
Marketer take
Rare pediatric epilepsy launch where genetic testing and epileptologist outreach drive patient finding.
- Sponsor company
- Praxis Precision Medicines (PRAX)
- Indication
- SCN2A and SCN8A developmental and epileptic encephalopathies (DEE)
- Therapeutic area
- Neurology, Rare disease
- Event
- PDUFA target action date
- Date
- Dec 27, 2026
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?